Jumping Before They Were Pushed – Kiadis And Aradigm Withdraw EU Filings
A Third Company, Actelion, Has Pulled An Indication Extension Request
Notice of the withdrawal of pan-EU marketing authorizations applications by Kiadis Pharma and Aradigm are noted in the agenda of the latest meeting of the European Medicines Agency's key scientific committee, the CHMP.
You may also be interested in...
Seven drugs, including two orphans and two generics, are on track to receive pan-EU approval.
It’s decision time again at the European Medicines Agency and Roche’s Polivy is one of the new drug applications that is up for a potential marketing recommendation.
The Dutch company's dataset on its stem cell transplant adjunct ATIR101 is not enough to satisfy European regulators as the standard of care in post-transplant patients has changed since the original filing.